Opinion|Videos|May 2, 2025
Payer-Related Barriers With Therapies Used for Uncomplicated UTIs
Panelists discuss how recurrent urinary tract infections (UTIs) treated with older antibiotics generate 2 to 3 times higher total costs than initial savings, warranting cost-effectiveness analyses in treatment decisions, whereas payers create barriers to newer therapies through restrictive authorizations, high co-pays, step therapy mandates, and limited formulary inclusion that providers can navigate via detailed documentation, pharmacy benefit manager engagement, patient assistance programs, and advocacy for evidence-based coverage policies.
Episodes in this series
Video content above is prompted by the following:
- To what extent does the economic burden of recurrence in patients treated with older, more affordable drugs offset the initial cost savings, and how should this affect treatment decisions?
- What payer-related barriers might arise for these emerging treatments for patients who have experienced treatment failure with traditional therapies?
- How can health care providers advocate for their patients in these situations?
Related to this article
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Trending on AJMC
1
Tavapadon for Parkinson Disease Approved by FDA
2
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
3
Baricitinib Approved for Severe Alopecia Areata in Adolescents
4
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
5